Albireo is an independent Swedish biotechnology company, which brings unique translational approaches to develop drugs that fulfil unmet medical needs in the gastrointestinal (GI) and liver disease areas. The team has a broad experience in drug development and has an extensive network in the international scientific and clinical communities.
Initiation of a Phase II Trial for A4250, the Company’s Lead Compound for Cholestatic Liver Diseases and NASH
Albireo’s Lead Compound in Cholestatic Liver Diseases, A4250, Protects Against Bile Acid-Mediated Cholestatic Liver Injury In Mice
Go to news archive
DDW - Washington DC, May 15-19, 2015
UEGW - Barcelona, Oct 24-28, 2015
AASLD - The Liver Meeting, San Fransisco, Nov 13-17, 2015